Laserfiche WebLink
Recipient governments do not need to have an official health or public health program in <br />order to utilize these eligible uses; any recipient can pursue these eligible uses, though Treasury <br />recommends consulting with health and public health professionals to support effective <br />implementation. <br />The CDC has provided recommendations and guidelines to help mitigate and prevent <br />COVID-19. The interim final rule and final rule help support recipients in stopping the spread of <br />COVID-19 through these recommendations and guidelines.70 The final rule reflects changing <br />circumstances of COVID-19 and provides a broad range of permissible uses for mitigating and <br />preventing the spread of the disease, in a manner consistent with CDC guidelines and <br />recommendations. <br />The purpose of the SLFRF funds is to mitigate the fiscal effects stemming from the <br />COVID-19 public health emergency, including by supporting efforts to stop the spread of the <br />virus. The interim final rule and final rule implement this objective by, in part, providing that <br />recipients may use SLFRF funds for COVID-19 mitigation and prevention.71 A program or <br />service that imposes conditions on participation in or acceptance of the service that would <br />undermine efforts to stop the spread of COVID-19 or discourage compliance with <br />recommendations and guidelines in CDC guidance for stopping the spread of COVID-19 is not a <br />permissible use of funds. In other words, recipients may not use funds for a program that <br />undermines practices included in the CDC's guidelines and recommendations for stopping the <br />spread of COVID-19. This includes programs that impose a condition to discourage compliance <br />with practices in line with CDC guidance (e.g., paying off fines to businesses incurred for <br />70 See Centers for Disease Control and Prevention, COVID-19, https://www.cdc.gov/coronavirus/2019- <br />ncov/index.html (last visited November 8, 2021). <br />71 See 35.6(b); IFR discussion of CDC guidelines. <br />58 <br />